We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Health Catalyst (HCAT) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Wall Street analysts expect Health Catalyst (HCAT - Free Report) to post quarterly loss of $0.01 per share in its upcoming report, which indicates a year-over-year increase of 80%. Revenues are expected to be $73.67 million, up 6.5% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Health Catalyst metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Revenue- Professional services' at $27.71 million. The estimate suggests a change of +13.1% year over year.
Based on the collective assessment of analysts, 'Revenue- Technology' should arrive at $46.05 million. The estimate points to a change of +3.1% from the year-ago quarter.
Analysts predict that the 'Adjusted Gross Profit- Professional Services' will reach $3.20 million. The estimate is in contrast to the year-ago figure of $4.33 million.
Analysts' assessment points toward 'Adjusted Gross Profit- Technology' reaching $31.43 million. The estimate compares to the year-ago value of $30.73 million.
Health Catalyst shares have witnessed a change of +6.5% in the past month, in contrast to the Zacks S&P 500 composite's +5.2% move. With a Zacks Rank #2 (Buy), HCAT is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Health Catalyst (HCAT) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts expect Health Catalyst (HCAT - Free Report) to post quarterly loss of $0.01 per share in its upcoming report, which indicates a year-over-year increase of 80%. Revenues are expected to be $73.67 million, up 6.5% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Health Catalyst metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Revenue- Professional services' at $27.71 million. The estimate suggests a change of +13.1% year over year.
Based on the collective assessment of analysts, 'Revenue- Technology' should arrive at $46.05 million. The estimate points to a change of +3.1% from the year-ago quarter.
Analysts predict that the 'Adjusted Gross Profit- Professional Services' will reach $3.20 million. The estimate is in contrast to the year-ago figure of $4.33 million.
Analysts' assessment points toward 'Adjusted Gross Profit- Technology' reaching $31.43 million. The estimate compares to the year-ago value of $30.73 million.
View all Key Company Metrics for Health Catalyst here>>>
Health Catalyst shares have witnessed a change of +6.5% in the past month, in contrast to the Zacks S&P 500 composite's +5.2% move. With a Zacks Rank #2 (Buy), HCAT is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>